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1. INTRODUCTION nearly complete inhibition for a response to be 
observable. 
y-Glutamyltransferase (y-GT) is a membrane- 
bound glycoprotein [ 1,2] reacting with substrates 
present in the extracellular milieu 131. Renal y-GT is 
present on the brush border of both convoluted and 
straight portions of the proximal tubule ]3,4] al- 
though some 2.5times more concentrated on the 
latter [4,5]. In addition a small but significant por- 
tion of the total renal activity is present in the anti- 
luminal region [6,7] associated at least in part, with 
the microvascular compartment [8]. The fact that 
the bulk of the total renal y-GT is present on the 
luminal border and that the substrate delivery to 
this site is limited by the glomerular filtration rate 
suggested that the reaction catalyzed by y-GT at 
this site would be substrate limited; in contrast, the 
high substrate delivery and low enzyme level sug- 
gested that the reaction might be enzyme-limited at 
the antiluminal site. To examine this possibility we 
employed AT-125 (L-(a-amino-3-chloro-4,5-dihy- 
dro-5-isoxazoleacetic acid) as an inhibitor of the in 
situ y-GT and measured the response at both lumi- 
nal and antiluminal sites as a function of total en- 
zyme activity. y-Glutamyl-p-nitroanilide (y-GpNA) 
rather than glutathione was used as the substrate to 
avoid the complication introduced by the gluta- 
thione oxidation [9]. The response was evaluated in 
terms ofp-nitroaniline @-NA) formation (largely a 
function of the antiluminal site) and in terms of 
filtered y-GpNA escaping into the urine (a function 
of the brush border enzyme activity). The results to 
follow are consistent with the interpretation that the 
blood side reaction is enzyme-limited, and there- 
fore most susceptible to inhibition, and that the 
brush border enzyme is substrate-limited, requiring 
2. MATERIALS AND METHODS 
Kidneys were obtained from male Sprague- 
Dawley rats (350-450 g body wt). The kidneys were 
isolated as in [lo] and perfused with an artificial 
plasma solution [ 1 l] containing [‘4C]methoxyin- 
ulin and 2 mM y-GpNA at pH 7.4 (95% 02:5% 
CO2). Perfusate and urine samples were collected at 
timed intervals and analyzed for y-GpNA and 
p-NA concentration (61 and 14C by liquid scintilla- 
tion spectrometry; glomerular filtration rate (GFR) 
was estimated from the urine: plasma 14C ratio x 
urine flow. Left non perfused and right perfused 
kidneys from each animal were homogenized and 
assayed for y-GT activity [ 121; homogenate protein 
concentration was analyzed as in [13]. Total renal 
y-GT activity determined in vitro is taken as spec. 
act. x renal protein content; in situ activity of the 
perfused kidney is taken as the amount of p-NA 
formed (perfusate + urine) unit time per kidney. 
For inhibition studies, kidneys were pre-perfused 
for 30 min with AT-125 (kindly supplied by Dr 
Ruth Davis, National Institute of Health) at 1.8-24 
nmol/kidney after which the perfusate was re- 
placed by means of a 3-way stop-cock [14] with a 
fresh media containing y-GpNA. Renal tissue levels 
of y-GpNA were measured after perfusion of con- 
trol and AT-125-treated kidneys; kidneys were 
promptly homogenized at the termination of per- 
fusion in 10% ice-cold trichloroacetic acid, neutral- 
ized and analyzed enzymatically using purified 
y-GT 161; y-GpNA content is expressed as pmol/g 
wet wt after subtracting the pre-formed p-NA con- 
tent. 
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3. RESULTS 
Fig. 1 shows the fall in perfusate y-GpNA and rise 
in p;NA over the perfusion course in both the per- 
fusate and urine compartments. The control rate of 
p-NA formation over this time course was 1.53 +- 
0.26 pmol. min-’ . g-‘, representing p-NA relea- 
sed into the perfusate + urine; after AT-125, the 
rate fell to < lo%, 0.12 + 0.05 pm01 . min-’ . g-l. 
The rate of y-GpNA disappearance from the per- 
fusate in control, 1.75 2 0.15 pm01 . min -* . -’ 
was slightly greater than p-NA formation due 
to the synthesis of y-glutamylpeptides appearing 
in the perfusate [6]; the disappearance in the AT- 
125-treated kidneyq0.60 + 0.36pmol. min -* . g -* 
cannot be attributed to tissue accumulation 
(tissue levels 1.77 + 0.15 and 1.80 + 0.21 pmol/g 
in control and AT-125-treated kidneys). Rather 
this decrease reflects the loss of y-GpNA into 
the urine as well as the small residual activity of 
y-GT in converting y-GpNA to p-NA. Renal levels 
of y-GT were 1064 ? 91 nmol . min -’ . mg -’ in 
controls and 11 k 3 nmol . min -’ . g -’ after per- 
fusion in kidneys exposed to 6 nmol AT- 125. 
The renal handling of filtered y-GpNA is shown 
in table 1. In the control kidneys y-GpNA was de- 
livered to the brush border enzyme at the rate of 
0.69 f 0.25 pmol/min which is < 50% the rate of 
PERFUSATE 0 CONTROL 
120 1 . AT-125 
ACONTROL 
A AT- 125 
Fig.1. Effect of 6 nmol AT-125 on +GpNA disappear- 
ance from the perfusate and appearance in the urine as 
well as on the formation of p-NA. Results are means + 
SEM from 4 control and 4 AT-125treated perfused 
kidneys. 
Table 1 
Influence of AT- 12Y on the excretion of v-GpNA 
Y-GpNAp GFR Filtered &n v-GPNA~ Excreted FEbvGpNA yGpNA 
@mol/ml) (ml/min) (I*mol/min) (ml/min) (pmol/ml) @mol/min) (W) Urine 
Perfusate 
Control 
(4) 
+ 
SEM 
0.8 10 0.550 0.690 0.290 0.110 0.020 0.730 0.070 
0.174 0.080 0.250 0.044 0.065 0.008 0.730 0.049 
AT-125 
(4) 
f 1.400 0.400 0.620 0.250 1.640 0.340 61.670 1.250 
SEM 0.250 0.060 0.110 0.063 0.345 0.060 6.229 0.395 
P < 0.025 n.s. n.s. ns. < 0.005 < 0.0005 < 0.0005 co.01 
a Kidneys perfused with 6 nmol AT- 125;(4) equals number of kidneys 
b Fractional excretion of y-GpNA = Excreted y-GpNA/Filtered yGpNA X 100 
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% ACTIVITY 
Fig.2. Relationship between total renal y-GT activity and 
p-NA formation (0) and y-GpNA excretion (A); FE = 
fraction of filtered y-GpNA excreted. Renal y-GT activ- 
ity was reduced by pre-perfusion with increasing 
amounts of AT- 125 (see text for details). 
p-NA formation, 1.52 pmol/min. Of the yGpNA 
delivered, only 0.73% was excreted while the urine 
to perfusate y-GpNA ratio, U/P, was 0.07 +- 0.05 
indicative of a steep gradient between perfusate and 
urine. With AT-125, 62% of the filtered y-GpNA 
was excreted with a U/P ratio > 1 indicating that 
y-GT activity is at least in part responsible for this 
gradient; renal tissue y-GpNA to urine y-GpNA 
concentration ratios fell from 21 + 13 in control to 
2.1 + 1.1 withAT-125. 
The affect of exposing the kidney to various 
amounts of AT-125 on total renal y-GT activity, 
p-NA formation and y-GpNA excretion is shown in 
fig.2. After exposure to 1.8 nmol AT- 125 total renal 
activity fell to 45% while p-NA formation dropped 
to 1.17 pmol/min and y-GpNA excretion remained 
unchanged. With 4 nmol AT- 125, total y-GT activ- 
ity dropped 90% with a further reduction in p-NA 
formation and little increase in y-GpNA excretion. 
However, at greater AT-125 levels, renal y-GT 
activity was virtually eliminated resulting in a large 
rise in y-GpNA excretion, from 7% to > 50% of that 
filtered. At these levels of inhibition the urine to 
plasma y-GpNA ratio was > 1, similar to results in 
table 1. 
4. DISCUSSION 
y-Glutamyltransferase is present in the rat kidney 
in great excess. Some appreciation of this excess can 
be gained from considering y-GpNA conversion 
under optimum conditions, i.e., kidney homogen- 
ate, in which substrate would not be rate limiting. 
Under such conditions the total capacity to utilize 
y-GpNA approaches 200 pmol/min kidney (spec. 
act. 1000 nmol . min - ’ . mg protein - ' x kidney 
protein 200 mg/ 1.5 g kidney). In contrast the iso- 
lated kidney perfused with similar y-GpNA levels 
utilized only 1.5 pmol/min indicating the in situ 
enzyme is clearly limited by the conditions imposed 
by the intact preparation. It was to gain a clearer 
understanding of the relationship between renal 
enzymology and function which lead to this study. 
The delivery of substrate to the kidney is limited 
by the perfusate flow (here 30 ml/min) X perfusate 
]y-GpNA] which was initially 2 mM. However, de- 
livery of substrate to the brush border enzyme is 
further constricted by the GFR (-0.5 ml/min) x 
perfusate [y-GpNA]. Thus, under these conditions, 
the brush border site, containing some 80% [6] of the 
total kidney enzyme receives < 2% of the y-GpNA 
delivered to the kidney; in contrast the antiluminal 
site receives 98% of the delivered substrate. Conse- 
quently the reaction occurring at the brush border 
and antiluminal site might be expected to be sub- 
strate- and enzyme-limited, respectively. An inhibi- 
tor that had access to both sites and that binds 
(stoichiometrically) to the y-glutamyl donor site [ 151 
might be expected to reveal this asymetrical distri- 
bution. Giving AT-125 at a dose calculated to in- 
hibit -50% of the total renal enzyme significantly 
reduced p-NA formation, occurring predominant- 
ly at the enzyme-limited antiluminal region, and had 
no effect at the brush border where the reaction is 
substrate-limited (fig.2). Completely inhibiting 
y-GT with 6 nmol AT-125 results in virtual elimi- 
nation of p-NA formation and maximal y-GpNA 
excretion; although 40-50% of the filtered 
y-GpNA is not excreted and therefore reabsorbed, 
this appears to be a passive process since the U/P 
ratio > 1. Furthermore, the elimination of per- 
fusate to urine y-GpNA concentration differences 
indicates that y-GT activity maintains this gradient 
suggesting that this enzyme functions in vivo to 
ensure similar gradients of the natural substrates. 
In vivo the delivery of extrarenal substrate is lim- 
ited by the renal plasma flow and glomerular 
filtration rate. Under these conditions some 80% of 
the delivered glutathione is removed [ 16,171 while 
inhibiting y-GT 90% lowers this to 30% as a conse- 
23 
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quence of excretion [17] similar to fig.1. Thus the 
extraction fraction, 80%, exceeds the filtration frac- 
tion, 20-30s in vivo, an excess which is eliminated 
by inhibiting y-GT. These observations are consis- 
tent with antiluminal y-GT activity being respons- 
ible for 50% of the removed glutathione. Secretion 
of glutathione from blood to urine might also ac- 
count for the high extraction fraction; however, in- 
hibition of y-GT by AT-125 should diminish the 
extraction if it was in fact dependent upon secre- 
tion. Furthermore, in the isolated perfused kidney 
the excretion of the y-glutamyl donor never exceeds 
its filtration rate after y-GT inhibition indicating 
that at least for this substrate secretion is not appar- 
ent. Of course, it does not exclude the possibility 
that AT- 125 affects both y-GT and a secretory sys- 
tem for y-glutamyl substrates. Nevertheless, this 
study points to a significant role of the antiluminal 
site in utilization of y-glutamyl substrates and that 
this site, in view of the limited enzyme available 
relative to substrate, is most susceptible to inhibi- 
tion. In contrast, the luminal enzyme is present in 
3 lo-fold excess requiring near complete inhibition 
to reveal a maximal response. 
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